- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2017–2019 · research · R01
BRCA1 Function in Post-Damage Nuclear Foci
David Morse Livingston · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · research · R01
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · program · P50
SPORE in Myeloid Malignancies
Benjamin Levine Ebert · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · research · R25
Summer Program to Advance Research Careers (SPARC)
Edward J Benz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · research · R21
Immunotherapeutic Approaches Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
PediQUEST: Improving Children's Quality of Life through e-PROMS and Palliative Care
Joanne Wolfe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · research · R33
Maximum efficiency sequencing using nuclease-based mutation enrichment and digital barcodes
G. Mike Makrigiorgos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2018 · research · R01
PhI trial of dual PI3K/BRD4 inhibitor SF1126 in neuroblastoma IND124993 (12/2/14)
Steven Dubois · Dana-Farber Cancer Institute · funded by U.S. Food and Drug Administration
2017–2027 · research · R01
Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity
Kimmie Ng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · research · R01
Unlocking the Potential of PI3K Inhibition in CLL
Jennifer R Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R25
Young Empowered Scientists for ContinUed Research Engagement (YES for CURE)
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
Dissecting mechanisms of immunotherapy resistance in melanoma patients
Benjamin Izar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · award
In vivo discovery of functional T cell inhibitory pathways in glioblastoma
Nathan Mathewson · Dana-Farber Cancer Institute · funded by American Cancer Society
2017–2022 · career development · K08
Overcoming resistance in BCR-ABL-rearranged acute lymphoblastic leukemia
Mark A. Murakami · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
PediQUEST: Improving Children's Quality of Life through e-PROMS and Palliative Care
Joanne Wolfe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · research · R01
A systems biology approach for dissecting enhancer hierarchy
Guo-Cheng Yuan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
Unlocking the Potential of PI3K Inhibition in CLL
Jennifer R Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · research · R21
Reducing viral reservoirs by opening HIV-1 Env to antibody attack
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · grant · PRMRP
Bioenergetic Rescue of Mitochondrial Disease Mutations
Pere Puigserver · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2017–2020 · fellowship · F32
Characterization of genetic modifiers of bioenergetic rescue in mitochondrial disease cell lines
Christopher F. Bennett · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation Cancers
Jinbo Chen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · career development · K22
Single-cell analysis of mutagenesis: from mutational mechanisms to functional consequences
Cheng-Zhong Zhang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation Cancers
Jinbo Chen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · career development · K22
Single-cell analysis of mutagenesis: from mutational mechanisms to functional consequences
Cheng-Zhong Zhang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2027 · research · R01
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · career development · K22
Single-cell analysis of mutagenesis: from mutational mechanisms to functional consequences
Cheng-Zhong Zhang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · career development · K08
Improving Hospice Use for Patients with Blood Cancers
Oreofe Olukemi Odejide · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · program · P50
SPORE in Myeloid Malignancies
Benjamin Levine Ebert · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · research · R21
Primers: Combining Radiotherapy and Immunotherapy using next genertaion radiotherapy biomaterials
Wilfred Ngwa · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · grant · PRCRP
Precision Medicine in Platinum-Treated Lethal Bladder Cancer
Eliezer Van Allen · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2017–2020 · fellowship · F32
Cross-species identification and validation of synthetic lethal relationships with VHL inactivation
Hilary Elaine Nicholson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2021 · research · R01
Disseminating an Evidence-Based Tobacco Control intervention for School Teachers in India
Glorian C Sorensen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biology
Kimmie Ng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
Lili Wang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · research · R21
Development of molecular probes to investigate and drug the oncogenic Wnt/?-catenin/BCL9/B9L transcriptional complex
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
New Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB Loss
Matthew Gilbert Oser · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2021 · research · R01
A systems biology approach for dissecting enhancer hierarchy
Guo-Cheng Yuan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
Transcriptional Regulation of the Androgen Receptor in Prostate Cancer
David Yoshio Takeda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
Improving Hospice Use for Patients with Blood Cancers
Oreofe Olukemi Odejide · Dana-Farber Cancer Institute · funded by National Institutes of Health
